Roivant Sciences
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $55,132 | $28,930 | $37,140 | $37,101 |
Gross Profit | 48,621 | 24,518 | 33,472 | 33,835 |
EBITDA | -225,690 | -210,378 | -224,777 | -270,082 |
EBIT | -230,573 | -215,603 | -230,162 | -275,669 |
Net Income | 95,297 | -151,115 | 5,096,184 | -304,327 |
Net Change In Cash | 55,132 | 28,930 | 37,140 | 37,101 |
Free Cash Flow | -193,794 | -108,806 | -210,807 | -196,702 |
Cash | 5,683,923 | 6,535,706 | 6,670,810 | 1,408,231 |
Basic Shares | 781,627 | 802,859 | 844,461 | 770,227 |
Annual Financials
| Values in thousands | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
Revenue | $124,795 | $61,280 | $55,286 | $23,795 |
Gross Profit | 109,235 | 48,152 | 46,320 | 21,738 |
EBITDA | -996,515 | -1,107,578 | -1,499,830 | -510,503 |
EBIT | -1,018,551 | -1,134,000 | -1,505,762 | -985,269 |
Net Income | 4,348,926 | -1,230,024 | -924,116 | -900,233 |
Net Change In Cash | 124,795 | 61,280 | 55,286 | 23,795 |
Cost of Revenue | -388,200 | -67,642 | ||
Free Cash Flow | -766,650 | -856,083 | -695,165 | -557,944 |
Cash | 6,535,706 | 1,676,813 | 2,060,400 | 2,055,044 |
Basic Shares | 831,049 | 712,791 | 669,753 | 222,669 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | $0.12 |
2024-03-31 | -$0.19 |
2023-12-31 | -$0.30 |
2023-09-30 | -$0.40 |
